See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
The long-term prognosis for immunotactoid glomerulopathy is difficult to predict due to the rarity of the condition, but some studies suggest that 50% of patients will have end-stage kidney disease (ESKD) by 5 years after diagnosis. Patients with ESKD may either pursue dialysis or kidney transplantation. The disease may recur in the transplanted kidney. However, the degree and rate of recurrence remains unclear due to the rarity of this disease. Researchers believe the rate of progression of the disease in the transplanted kidney is slower than in the native kidney. The rate of recurrence seems to be higher in patients who have monoclonal gammopathy.
Last updated: 3/28/2014
- Immunotactoid Glomerulopathy. UNC Health Care Kidney Center. http://www.unckidneycenter.org/kidneyhealthlibrary/immunotactoid.html. Accessed 3/28/2014.
- Fervenza F, Sethi S, Appel G. Glomerular diseases due to nonamyloid fibrillar deposits. UpToDate. July 16, 2014; http://www.uptodate.com/contents/glomerular-diseases-due-to-nonamyloid-fibrillar-deposits. Accessed 8/19/2015.